ESR1 and neoplasm: Tumor subtypes rates were 60.9% (84/138), 10.9% (15/138) and 28.3% (39/138) before 2005, 48.7% (190/390), 20.5% (80/390) and 30.8% (120/390) since 2005, for TNBC, ER- Her2+ and ER+ Her2+ BC, respectively (p=0.015).